Citation
J Haem Pract 2014; 1(2):J Haem Pract 2014; 1(2): 8-10. doi: 10.17225/jhp00017

Authors: Poornima Kumar, Ri Liesner, Kate Khair, Mary Mathias, Jemma Efford

Poornima Kumar
Consultant Haematologist
Luton and Dunstable Hospital, The L&D Hospital NHS Foundation Trust, Lewsey Rd, Luton, Bedfordshire LU4 0DZ, UK.

Ri Liesner
Consultant Haematologist
Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK.

Kate Khair
Nurse Consultant Haemophilia
Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK.

Mary Mathias
Consultant Haematologist
Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK.

Jemma Efford
Clinical Nurse Specialist - Haemophilia
Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK.

Abstract

Severe factor X deficiency is a rare serious bleeding disorder historically treated with fresh frozen plasma (FFP) and more recently with prothrombin complex concentrate (PCC) which contains activated factors II, VII, IX and X. The infusion volume of PCC is smaller than FFP, but there is a risk of thromboembolic complications given the presence of activated forms of vitamin K-dependent factor concentrates when treating an isolated coagulation factor deficiency.

Acknowledgements

Preparation and publication of this case study has been made possible by a grant from Bio Products Laboratory Ltd, the manufacturer of BPL Factor X concentrate, to the publisher. The manuscript was written by the authors independently of the sponsor.

References

  1. Brown DL, Kouides P Diagnosis and treatment of inherited factor X deficiency. Haemophilia 2008; 14: 1176-82
  2. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost 2009; 35(4): 407–415.
  3. European Medicines Agency: Pre-authorisation evaluation of medicines for human use. Public summary of positive opinion for orphan designation of human coagulation factor X for the treatment of hereditary factor X deficiency. Doc Ref: EMEA/COMP/138276/2008. Available at http://www.emea.europa.au. [Accessed 20/12/11]
  4. Auerswald G. Prophylaxis in rare coagulation disorders – factor X deficiency. Thromb Res 2006; 118(s1): s29-31.
  5. A Study Investigating Treatment Factor X in People With Factor X Deficiency. www.clinicaltrials.gov [Accessed 26/04/2014].
  6. UK Muscular Dystrophy Campaign. MDC1A fact sheet. Available from www.muscular-dystrophy.org (accessed 10/04/2014).

The Journal of Haemophilia Practice is published by Haemnet.

Haemnet is a registered charity that brings together and gives a voice to haemophilia nurses, physiotherapists and allied health care professionals, providing forums for collaborative research, educational activities and support.